Literature DB >> 28492921

Interim Safety Data Comparing Ranibizumab With Panretinal Photocoagulation Among Participants With Proliferative Diabetic Retinopathy.

Jeffrey G Gross1, Adam R Glassman2, Margaret J Klein2, Lee M Jampol3, Frederick L Ferris4, Neil M Bressler5, Roy W Beck2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28492921      PMCID： PMC5847077          DOI： 10.1001/jamaophthalmol.2017.0969

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN： 2168-6165            Impact factor:   7.389


× No keyword cloud information.
  5 in total

1.  Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.

Authors:  Jeffrey G Gross; Adam R Glassman; Lee M Jampol; Seidu Inusah; Lloyd Paul Aiello; Andrew N Antoszyk; Carl W Baker; Brian B Berger; Neil M Bressler; David Browning; Michael J Elman; Frederick L Ferris; Scott M Friedman; Dennis M Marcus; Michele Melia; Cynthia R Stockdale; Jennifer K Sun; Roy W Beck
Journal:  JAMA       Date:  2015-11-24       Impact factor: 56.272

Review 2.  Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema: A Systematic Review and Meta-analysis.

Authors:  Robert L Avery; Gabriel M Gordon
Journal:  JAMA Ophthalmol       Date:  2016-01       Impact factor: 7.389

Review 3.  Anti-vascular endothelial growth factor for diabetic macular oedema.

Authors:  Gianni Virgili; Mariacristina Parravano; Francesca Menchini; Jennifer R Evans
Journal:  Cochrane Database Syst Rev       Date:  2014-10-24

4.  Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).

Authors:  Jai N Patel; Chen Jiang; Daniel L Hertz; Flora A Mulkey; Kouros Owzar; Susan Halabi; Mark J Ratain; Paula N Friedman; Eric J Small; Michael A Carducci; John F Mahoney; Michael J Kelley; Michael J Morris; William K Kelly; Howard L McLeod
Journal:  Cancer       Date:  2014-11-21       Impact factor: 6.860

5.  Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-08
  5 in total
  5 in total

1.  Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.

Authors:  Jeffrey G Gross; Adam R Glassman; Danni Liu; Jennifer K Sun; Andrew N Antoszyk; Carl W Baker; Neil M Bressler; Michael J Elman; Frederick L Ferris; Thomas W Gardner; Lee M Jampol; Daniel F Martin; Michele Melia; Cynthia R Stockdale; Roy W Beck
Journal:  JAMA Ophthalmol       Date:  2018-10-01       Impact factor: 7.389

2.  Decision Making in Proliferative Diabetic Retinopathy Treatment.

Authors:  Mary B Kansora; Raquel Goldhardt
Journal:  Curr Ophthalmol Rep       Date:  2019-02-04

3.  Changes in Blood Pressure and Urine Albumin-Creatinine Ratio in a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.

Authors:  Adam R Glassman; Danni Liu; Lee M Jampol; Jennifer K Sun
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-03-01       Impact factor: 4.799

Review 4.  Review of Studies Comparing Panretinal Photocoagulation and Anti-Vascular Endothelial Growth Factor Therapy in the Treatment of Proliferative Diabetic Retinopathy.

Authors:  Thiruvarasu Gunasekaran; Yuarrani Gunasekaran; Pua Tze Hui
Journal:  Cureus       Date:  2022-02-21

Review 5.  A Paradigm Shift in the Management Approaches of Proliferative Diabetic Retinopathy: Role of Anti-VEGF Therapy.

Authors:  Rajiv Raman; Kim Ramasamy; Utkarsh Shah
Journal:  Clin Ophthalmol       Date:  2022-09-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.